GlassScriptPhysician profile
Srijan Valasapalli
NPI 1649832981
$4,679.39
in general payments reported to CMS, 2019-2025
29 companies · $618 in 2025
The $618 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.37 · 2022: $645 · 2023: $1,870 · 2024: $1,528 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,658 · Education: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,657.84 |
| Education | $358.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $903.04 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $875.72 | 2023-2025 | |
| Incyte Corporation | $319.11 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $261.60 | 2023 | Pomalyst, Reblozyl, Augtyro |
| Seagen INC. | $243.11 | 2022-2023 | Adcetris |
| Rigel Pharmaceuticals, INC. | $216.46 | 2024 | Rezlidhia, Tavalisse |
| Janssen Scientific Affairs, LLC | $161.37 | 2025 | Tecvayli, Carvykti, Darzalex |
| Beigene USA, INC. | $138.40 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $137.70 | 2024 | Imfinzi, Lynparza |
| Janssen Pharmaceuticals, INC | $137.69 | 2022-2023 | Xarelto |
| Alexion Pharmaceuticals, INC. | $129.49 | 2023-2025 | Soliris, Ultomiris |
| Pfizer INC. | $125.22 | 2023-2025 | |
| Sobi, INC | $125.00 | 2022 | |
| Eusa Pharma (US) LLC | $123.37 | 2022 | |
| Jazz Pharmaceuticals INC. | $106.10 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $101.59 | 2024 | |
| Eisai INC. | $101.21 | 2023-2025 | |
| Janssen Biotech, INC. | $82.34 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Sanofi-Aventis U.S. LLC | $81.99 | 2023 | |
| Abbvie INC. | $70.45 | 2023-2024 | Venclexta |
| Pharmacosmos Therapeutics INC. | $45.30 | 2023 | Monoferric |
| Amgen INC. | $42.75 | 2023 | Blincyto, Kyprolis |
| Astellas Pharma US INC | $42.69 | 2023-2024 | Cresemba, Xospata |
| Novartis Pharmaceuticals Corporation | $22.25 | 2023 | |
| Sumitomo Pharma America, INC. | $20.07 | 2024 | Orgovyx |
| Medical Device Business Services, INC. | $18.37 | 2019 | |
| Daiichi Sankyo INC. | $18.16 | 2024 | Vanflyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.42 | 2024 | Xifaxan |
| Exelixis INC. | $14.42 | 2023 | Cabometyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srijan Valasapalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.